Biotech News
Related news
ABUSArbutus2026-08-21 11:30 EST
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-04-15 11:30 EST
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
ASMBAssembly Biosciences2026-05-26 20:05 EST
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
ASMBAssembly Biosciences2026-05-22 11:05 EST
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
ANTXAN2 Therapeutics2026-03-09 11:00 EST
AN2 Therapeutics Announces $40 Million Private Placement Financing
ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
ENTAEnanta Pharmaceuticals2026-03-30 11:00 EST
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists (AAI)
Arbutus
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...
Recent company news
ABUSArbutus2026-08-24 11:30 EST
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
ABUSArbutus2026-08-21 11:30 EST
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-08-12 11:30 EST
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ABUSArbutus2026-07-16 11:30 EST
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
ABUSArbutus2026-05-13 11:30 EST
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Stock data
- Close
- 5.21 USD
- Market cap
- 841.51M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States